(1-methyl-pyrrolidin-2-yl)-acetaldehyde | 86889-68-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (1-methyl-pyrrolidin-2-yl)-acetaldehyde
• 英文别名: 2-(1-Methylpyrrolidin-2-yl)acetaldehyde
• CAS: 86889-68-1
• 化学式: C₇H₁₃NO
• 分子量: 127.186
• InChiKey: PPNSGZWFXWAMND-UHFFFAOYSA-N

物化性质

• 沸点：
  79-80 °C(Press: 15-16 Torr)
• 密度：
  0.944±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  聚合甲醛 、 alkaline earth salt of/the/ methylsulfuric acid 在 盐酸 作用下， 生成 (1-methyl-pyrrolidin-2-yl)-acetaldehyde
  参考文献：
  名称：

  Hess; Merck; Uibrig, Chemische Berichte, 1915, vol. 48, p. 1892

  摘要：

  DOI：

文献信息

• MGluR5 modulators IV
  申请人：Isaac Methvin

  公开号：US20070259923A1

  公开（公告）日：2007-11-08

  The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.

  本发明涉及新型化合物，以及其制备方法、在治疗中的应用和包含这些新型化合物的药物组合物。
• Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
  申请人：Eckhardt Matthias

  公开号：US20110028445A1

  公开（公告）日：2011-02-03

  The present invention relates to compounds defined by formula (I) wherein the groups A, B, X, m, n and o are defined as in claim 1 , possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11 β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity and dyslipidemia.

  本发明涉及由式(I)定义的化合物，其中A，B，X，m，n和o的基团如权利要求1中所定义，具有有价值的药理活性。特别地，这些化合物是11β-羟基类固醇脱氢酶（HSD）1的抑制剂，因此适用于治疗和预防可以通过抑制该酶而受到影响的疾病，如代谢性疾病，特别是2型糖尿病，肥胖症和血脂异常。
• Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
  申请人：FEDORA PHARMACEUTICALS INC.

  公开号：US10030019B2

  公开（公告）日：2018-07-24

  A compound of formula (I): wherein: M is hydrogen or a pharmaceutically acceptable salt-forming cation; Y is OR1 or NR2R3, and R1, R2, R3 and M are as defined herein. Also, methods of treating bacterial infection, pharmaceutical compositions, molecular complexes and processes for preparing compounds.

  式 (I) 的化合物： 其中 M 是氢或药学上可接受的成盐阳离子； Y 是 OR1 或 NR2R3、 以及 R1、R2、R3 和 M 如本文所定义。此外，还有治疗细菌感染的方法、药物组合物、分子复合物和制备化合物的工艺。
• Chemokine CXCR4 Receptor Modulators and Uses Related Thereto
  申请人：Emory University

  公开号：US20200054623A1

  公开（公告）日：2020-02-20

  The disclosure relates to chemokine CXCR4 receptor modulators and uses related thereto. The receptor modulators can be formulated to form pharmaceutical compositions comprising the disclosed compounds or pharmaceutically acceptable salts or prodrugs thereof. The compositions may be used for managing CXCR4 related conditions, typically prevention or treatment of viral infections abnormal cellular proliferation, retinal degeneration, inflammatory diseases, or as an immunostimulant or immunosuppressant or for managing cancer and may be administered with another active ingredient such as an antiviral agent or chemotherapeutic agent.
• [EN] 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE<br/>[FR] DÉRIVÉS DE 7-AZAINDOLE ET LEUR UTILISATION DANS L'INHIBITION DE C-JUN N-TERMINAL KINASE
  申请人：EISAI LONDON RES LAB LTD

  公开号：WO2008095944A1

  公开（公告）日：2008-08-14

  [EN] The present invention provides a compound of formula (I); or a pharmaceutically acceptable salt thereof, the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the inhibition of c-Jun N-terminal kinase (JNK) activity and the use in medicine and particularly in the treatment of neurodegenerative disorders, inflammatory diseases and/or and autoimmune diseases. The invention also provides processes for the manufacture of said compounds of formula (I) or a pharmaceutically acceptable salt thereof and compositions containing them.
  [FR] La présente invention porte sur un composé de formule (I) ou un sel pharmaceutiquement acceptable de celui-ci ; sur l'utilisation de composé de formule (I) ou d'un sel pharmaceutiquement acceptable de celui-ci dans l'inhibition de l'activité C-Jun N-terminal kinase (JNK) ; et sur l'utilisation en médecine et, en particulier, dans le traitement de troubles neurodégénératifs, de maladies inflammatoires et/ou de maladies auto-immunes. L'invention porte également sur des procédés de fabrication desdits composés de formule (I) ou sur un sel pharmaceutiquement acceptable de ceux-ci, et sur des compositions les contenant.